NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis $0.31 -0.01 (-1.59%) As of 09:32 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC Filings About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANEB alerts:Sign Up Key Stats Today's Range$0.31▼$0.3150-Day Range$0.30▼$0.4252-Week Range$0.00▼$2.85Volume100 shsAverage Volume26,741 shsMarket Capitalization$12.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care. Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings. The product remains investigational and has not been approved for commercial use. Based in Austin, Texas, Anebulo conducts its development activities through clinical research and pharmaceutical collaborations. The company was established to pursue therapies for acute cannabinoid-related conditions and is led by Chief Executive Officer Simon Allen.AI Generated. May Contain Errors. Read More Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANEB Stock News HeadlinesANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc (ANEB) Stock Price, Quote, News & HistoryJuly 1, 2026 | benzinga.comAnebulo’s Selonabant Phase 1 Completion: What Investors Should Watch NextMay 8, 2026 | tipranks.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 15 at 1:00 AM | Stansberry Research (Ad)Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesFebruary 13, 2026 | finance.yahoo.comAnebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plansFebruary 6, 2026 | in.investing.comAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECFebruary 6, 2026 | finance.yahoo.comAnebulo Pharmaceuticals Announces Final Results of Tender OfferJanuary 29, 2026 | finance.yahoo.comAnebulo Pharmaceuticals Announces Preliminary Results of Tender OfferJanuary 27, 2026 | businesswire.comSee More Headlines ANEB Stock Analysis - Frequently Asked Questions How have ANEB shares performed this year? Anebulo Pharmaceuticals' stock was trading at $1.01 at the beginning of the year. Since then, ANEB shares have decreased by 69.3% and is now trading at $0.31. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) posted its earnings results on Monday, September, 29th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings9/29/2025Today10/15/2026Next Earnings (Estimated)11/18/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ANEB's financial health is in the Red zone, according to TradeSmith. ANEB has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANEB CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.57% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.11Miscellaneous Outstanding Shares40,785,000Free Float7,912,000Market Cap$12.64 million OptionableNot Optionable Beta-1.88 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ANEB) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
